Clonal Hematopoiesis and therapy related MDS/AML

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Clonal hematopoiesis (CH) involves mutations in blood cells, often linked to aging.
• It's considered a pre-malignant state, potentially influenced by cellular stress.
• Therapy-related myeloid neoplasms (t-MNs) are aggressive cancers post-chemotherapy/radiation.

Purpose of the Study:

• To review the clinical association between CH and t-MN risk.
• To explore mechanisms driving CH under cellular stress.
• To provide follow-up and prevention strategies for CH patients.

Main Methods:

• Review of clinical evidence linking CH to t-MNs.
• Discussion of molecular mechanisms of clonal expansion.
• Synthesis of recommendations for patient management.

Main Results:

• CH mutations can be triggered by cytotoxic damage and stem cell expansion.
• Evidence suggests CH is a risk factor for developing t-MNs.
• Understanding mechanisms aids in predicting risk and developing interventions.

Conclusions:

• CH is a significant risk factor for therapy-related myeloid neoplasms.
• Further research into mechanisms and prevention strategies is warranted.
• Clinical monitoring of CH patients is crucial for early detection and intervention.